Bangkok, Bangkok Genomics Innovation PCL. A world-class provider of medical diagnosis using cutting-edge genetic technology. Ready to trade on the Stock Exchange on March 20, with a security value at the IPO price of 978 million baht, using the abbreviation "BKGI" in securities trading. Mr. Manphong Senanarong, Deputy Manager, Head of Securities Issuer Division The Stock Exchange of Thailand revealed that the Stock Exchange welcomes Bangkok Genomics Innovation Public Company Limited. Listed and started trading on the stock exchange in the service industry group Medical business category Using the securities trading abbreviation "BKGI" on March 20, 2024. BKGI operates a business providing laboratory services and medical diagnosis. The main service is the examination and screening of chromosomal abnormalities in the fetus from the mother's blood. (Non-Invasive Prenatal Testing : NIPT) under the brand 'NIFTY' that has gained wide popularity. Screening for carriers of genetic diseases and cancer With advanc ed Next - Generation Sequencing (NGS) technology that provides accurate and fast analysis results. and provides services covering analysis of infectious disease groups and sell products Other equipment sets By providing services that meet the needs of having a better quality of life at all ages. Under the main support of BGI Group, the major shareholder which is As one of the world leaders in genetic decoding research and the application of cutting-edge bioinformatics technology, BKGI has always earned the trust of its users. BKGI has a paid-up capital of 300 million baht with a par value of 0.5 baht per share, consisting of 440 million existing common shares and 160 million additional common shares offered for sale to the public for the first time (IPO), offered for sale to 1) individuals. At the discretion of the underwriter, not less than 120 million shares. 2) Company benefactors, not more than 24 million shares. 3) Directors, executives, and employees of the company, not more than 16 million shares, between 12 - 14 March. 2024, the price per share is 1.63 baht, representing a fundraising value of 260.80 million baht, with a securities value at the IPO price of 978 million baht, with Finansia Syrus Securities Public Company Limited serving as the financial advisor and underwriter and Guaranteed distribution of common shares Dr. Saowalak Dansakul, Chief Executive Officer of Bangkok Genomics Innovation Public Company Limited (BKGI), revealed that the listing on the Stock Exchange of Thailand Will support the company to grow according to the strategy that has been laid out in both business and raising the level of public health in Thailand. The money raised from fundraising will be used as revolving capital. and expand the medical business, Genomics, for medical treatment and health care to promote good health in every stage of life. Stepping into being a leading organization in modern science Using high technology To develop the quality of life of the country's population BKGI has the top 3 shareholders after the IPO: 1) BGI Health (HK) Co., Ltd, holding 37.40% of shares, 2) Mr. Preecha Laohapongchana, holding 12.22% of shares, and 3) Mr. Ratchaphol Asawinwijit, holding 7.73% of shares. The determination of the IPO price is based on the ratio of share price to net income per share (Price to Earnings Ratio: P/E) equal to 30.43 times, which is calculated from net profit. During the past 4 quarters From January 1, 2023 to December 31, 2023 divided by the total number of issued and paid common shares of the Company. After this offering of shares (Fully Diluted), the net profit per share (Earnings Per Share) is equal to 0.05 baht. The Company has a policy of paying dividends at a rate of not less than 40 percent of the net profit from the separate financial statements. Company's business After deducting corporate income tax and allocation of legal reserves. Investors and interested parties Details can be viewed from the company's prospectus at the SEC's website at www.sec.or.th. and general information of the c ompany at www.bangkokgenomics.com and at www.set.or.th Source: Thai News Agency

Bangkok, Bangkok Genomics Innovation PCL. A world-class provider of medical diagnosis using cutting-edge genetic technology. Ready to trade on the Stock Exchange on March 20, with a security value at the IPO price of 978 million baht, using the abbreviation "BKGI" in securities trading. Mr. Manphong Senanarong, Deputy Manager, Head of Securities Issuer Division The Stock Exchange of Thailand revealed that the Stock Exchange welcomes Bangkok Genomics Innovation Public Company Limited. Listed and started trading on the stock exchange in the service industry group Medical business category Using the securities trading abbreviation "BKGI" on March 20, 2024. BKGI operates a business providing laboratory services and medical diagnosis. The main service is the examination and screening of chromosomal abnormalities in the fetus from the mother's blood. (Non-Invasive Prenatal Testing : NIPT) under the brand 'NIFTY' that has gained wide popularity. Screening for carriers of genetic diseases and cancer With advanc ed Next - Generation Sequencing (NGS) technology that provides accurate and fast analysis results. and provides services covering analysis of infectious disease groups and sell products Other equipment sets By providing services that meet the needs of having a better quality of life at all ages. Under the main support of BGI Group, the major shareholder which is As one of the world leaders in genetic decoding research and the application of cutting-edge bioinformatics technology, BKGI has always earned the trust of its users. BKGI has a paid-up capital of 300 million baht with a par value of 0.5 baht per share, consisting of 440 million existing common shares and 160 million additional common shares offered for sale to the public for the first time (IPO), offered for sale to 1) individuals. At the discretion of the underwriter, not less than 120 million shares. 2) Company benefactors, not more than 24 million shares. 3) Directors, executives, and employees of the company, not more than 16 million shares, between 12 - 14 March. 2024, the price per share is 1.63 baht, representing a fundraising value of 260.80 million baht, with a securities value at the IPO price of 978 million baht, with Finansia Syrus Securities Public Company Limited serving as the financial advisor and underwriter and Guaranteed distribution of common shares Dr. Saowalak Dansakul, Chief Executive Officer of Bangkok Genomics Innovation Public Company Limited (BKGI), revealed that the listing on the Stock Exchange of Thailand Will support the company to grow according to the strategy that has been laid out in both business and raising the level of public health in Thailand. The money raised from fundraising will be used as revolving capital. and expand the medical business, Genomics, for medical treatment and health care to promote good health in every stage of life. Stepping into being a leading organization in modern science Using high technology To develop the quality of life of the country's population BKGI has the top 3 shareholders after the IPO: 1) BGI Health (HK) Co., Ltd, holding 37.40% of shares, 2) Mr. Preecha Laohapongchana, holding 12.22% of shares, and 3) Mr. Ratchaphol Asawinwijit, holding 7.73% of shares. The determination of the IPO price is based on the ratio of share price to net income per share (Price to Earnings Ratio: P/E) equal to 30.43 times, which is calculated from net profit. During the past 4 quarters From January 1, 2023 to December 31, 2023 divided by the total number of issued and paid common shares of the Company. After this offering of shares (Fully Diluted), the net profit per share (Earnings Per Share) is equal to 0.05 baht. The Company has a policy of paying dividends at a rate of not less than 40 percent of the net profit from the separate financial statements. Company's business After deducting corporate income tax and allocation of legal reserves. Investors and interested parties Details can be viewed from the company's prospectus at the SEC's website at www.sec.or.th. and general information of the c ompany at www.bangkokgenomics.com and at www.set.or.th Source: Thai News Agency